LTR Pharma Ltd

AU:LTP Australia Biotechnology
Market Cap
$48.39 Million
AU$78.14 Million AUD
Market Cap Rank
#23886 Global
#480 in Australia
Share Price
AU$0.43
Change (1 day)
+0.00%
52-Week Range
AU$0.28 - AU$0.74
All Time High
AU$2.06
Categories
Companies in Australia Biotechnology
About

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more

LTR Pharma Ltd (LTP) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of December 2024: -0.070x

Based on the latest financial reports, LTR Pharma Ltd (LTP) has a cash flow conversion efficiency ratio of -0.070x as of December 2024.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.39 Million) by net assets (AU$34.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

LTR Pharma Ltd - Cash Flow Conversion Efficiency Trend (2022–2024)

This chart illustrates how LTR Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

LTR Pharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of LTR Pharma Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Molinos Juan Semino SA
BA:SEMI
 		0.001x
Live Verdure Ltd
AU:LV1
 		-0.448x
Advagene Biopharma Co. Ltd.
TWO:6709
 		0.000x
Auric Mining Ltd
AU:AWJ
 		0.143x
Spanish Mountain Gold Ltd.
OTCQB:SPAUF
 		0.001x
TIL Limited
NSE:TIL
 		-0.256x
ProMIS Neurosciences Inc.
NASDAQ:PMN
 		-1.108x
Lien Chang Electronic Enterprise Co Ltd
TW:2431
 		-0.008x

Annual Cash Flow Conversion Efficiency for LTR Pharma Ltd (2022–2024)

The table below shows the annual cash flow conversion efficiency of LTR Pharma Ltd from 2022 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-06-30 AU$2.94 Million AU$-5.09 Million -1.732x -133.74%
2023-06-30 AU$2.07 Million AU$-1.54 Million -0.741x -130.74%
2022-06-30 AU$1.77 Million AU$-568.18K -0.321x --